All > Recurrent Glioblastoma > Lynparza

Pembrolizumab for Glioblastoma (GBM)

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Glioblastoma (GBM)+1 MorePembrolizumab - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is studying a combination of drugs as a possible treatment for recurrent glioblastoma (GBM), a brain tumor.

Eligible Conditions
  • Glioblastoma (GBM)
  • Glioblastoma

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Pembrolizumab
1
Stereotactic radiosurgery (SRS)
1
IDO1 Inhibitor BMS-986205

Study Objectives

2 Primary · 4 Secondary · Reporting Duration: 24 months

24 months
Grade 3 or Higher Treatment-Related Toxicity Rate
Median Overall Survival (OS)
Objective Response Rate (ORR)
Month 6
6-month Progression-Free Survival (PFS6)
Day 14
Gene expression profiling (GEP) score
Tumor infiltrating lymphocytes (TIL) Density

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Pembrolizumab
1
Stereotactic radiosurgery (SRS)
1
IDO1 Inhibitor BMS-986205

Side Effects for

Pembrolizumab Second Course
100%Parkinsonism
100%Urinary tract infection
100%Inappropriate antidiuretic hormone secretion
This histogram enumerates side effects from a completed 2021 Phase 3 trial (NCT03066778) in the Pembrolizumab Second Course ARM group. Side effects include: Parkinsonism with 100%, Urinary tract infection with 100%, Inappropriate antidiuretic hormone secretion with 100%.

Trial Design

3 Treatment Groups

Cohort 1 (Safety Lead In): pembrolizumab plus olaparib and temozolomide
1 of 3
Cohort 2 (Surgical Cohort): Arm B - Pembrolizumab monotherapy
1 of 3
Cohort 2 (Surgical Cohort): Arm A - Pembrolizumab plus olaparib and temozolomide
1 of 3

Experimental Treatment

78 Total Participants · 3 Treatment Groups

Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2

Cohort 1 (Safety Lead In): pembrolizumab plus olaparib and temozolomideExperimental Group · 3 Interventions: Temozolomide, Pembrolizumab, Olaparib · Intervention Types: Drug, Drug, Drug
Cohort 2 (Surgical Cohort): Arm B - Pembrolizumab monotherapy
Drug
Experimental Group · 1 Intervention: Pembrolizumab · Intervention Types: Drug
Cohort 2 (Surgical Cohort): Arm A - Pembrolizumab plus olaparib and temozolomideExperimental Group · 3 Interventions: Temozolomide, Pembrolizumab, Olaparib · Intervention Types: Drug, Drug, Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Temozolomide
2010
Completed Phase 3
~1940
Pembrolizumab
2017
Completed Phase 3
~2240
Olaparib
2017
Completed Phase 4
~2090

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 24 months

Who is running the clinical trial?

L. Nicolas Gonzalez Castro, MD, PhDLead Sponsor
Patrick Y. Wen, MDLead Sponsor
9 Previous Clinical Trials
700 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
3,684 Previous Clinical Trials
4,958,050 Total Patients Enrolled
Luis N Gonzalez Castro, MD, PhDPrincipal InvestigatorDana-Farber Cancer Institute
Patrick Y Wen, MDPrincipal InvestigatorDana-Farber Cancer Institute
4 Previous Clinical Trials
494 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You must be able to adhere to the dosing and visit schedules and agree to record medication times accurately and consistently in a daily diary.
You must be at least 18 years old to sign this consent form.
You are of childbearing potential and are not pregnant or breastfeeding.
You have a KPS ≥ 70 and ECOG Performance Status ≤ 1.
Participants must be able to swallow oral medications

Who else is applying?

What state do they live in?
Texas100.0%
What site did they apply to?
Massachusetts General Hospital100.0%
What portion of applicants met pre-screening criteria?
Met criteria100.0%
How many prior treatments have patients received?
0100.0%
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top